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INTRODUCTION
Chronic Myeloid Leukemia (CML) has historically represented one of the few "paradigm diseases" in the field of cancer research (1) (2) (3) . Indeed, CML has been one of the first malignancies associated with a known cytogenetic alteration (i.e. the Philadelphia chromosome) and a specific molecular hallmark (i.e. the BCR-ABL oncoprotein) (4, 5). Furthermore, specific BCR-ABL characteristics (e.g. constitutive tyrosine kinase activity, exclusive cytoplasmic localization) have been ingeniously targeted to devise innovative therapeutic strategies that have ushered the era of tailored cancer treatment (6, 7) .
Suppression of BCR-ABL catalytic activity by the Tyrosine Kinase Inhibitor (TKI) Imatinib Mesylate (IM) has dramatically improved the natural history of CML (5) . Despite the unparalleled results achieved by this drug, approximately 30% of CML patients fail IM (3) . To address this critical issue, second and third generation TKIs (e.g. Dasatinib and Ponatinib) have been generated and tested on IM-resistant individuals, enjoying early clinical success (8, 9) . However, more mature data suggest that up to 50% of patients receiving either Dasatinib (DAS) or Ponatinib (PON) will not obtain long-term benefit from these drugs and will progress to the advanced phases of the disease (10, 11) .
Multiple mechanisms have been proposed to explain TKIs failure. While this phenomenon can recognize different causes, point mutations in the BCR-ABL kinase domain (KD) are one of the most common reasons underlying TKI resistance (12) (13) (14) (15) . Substitution of Threonine 315 with an Isoleucine (T315I) represents the most problematic BCR-ABL mutation as alterations of this gatekeeper residue preserve the oncoprotein's kinase activity while inducing resistance to first and second generation TKIs (16, 17) . Furthermore, recent evidence suggests that the T315I substitution is associated with inferior overall and failure-free survival (18).
Since the mechanisms allowing different BCR-ABL mutants to avoid catalytic inhibition by first, second and third generation inhibitors are still partially unresolved, there is a clear need for a structural characterization of the interactions occurring between the BCR-ABL KD and different TKIs. Experimental measures and quantification of the delicate balance of different physico-chemical components are very difficult to obtain and a complete overview of the molecular determinants in the inhibitors binding modes is challenging for this class of flexible proteins. Molecular Dynamics (MD) investigations represent an ideal tool to extract energetic and dynamical features in binding processes and conformational equilibria. In this respect, computational studies 5 addressing BCR-ABL binding mechanisms can be grouped in three types of approaches: i) studies addressing the BCR-ABL KD alone, aimed at characterizing the equilibrium between the active and inactive conformations (19) (20) (21) ; ii) studies addressing binding to various inhibitors (22-24); and iii) studies evaluating the impact of mutations on BCR-ABL kinase activity (25-30). However, a comparative investigation of the binding modes and dynamics characterizing the interactions between the BCR-ABL kinase and different TKIs is still lacking.
By analyzing all reported BCR-ABL point mutations associated with TKI resistance (12-15), we noticed a lack of amino acidic substitutions involving four residues (E286, M318, I360 and D381) that are known to generate hydrogen bond interactions with PON (31) (Fig. 1A) . The same residues (with the addition of T315) also generate hydrogen bonds with IM (32) (Fig. 1B) , while T315 and M318 are the only amino acids forming hydrogen bonds with DAS (33) (Fig. 1C) . We therefore employed a combined experimental and computational approach to investigate the effects of different mutations on these amino acids. Our results shed light on the molecular details underlying the essential role of E286, M318, I360 and D381 in preserving BCR-ABL kinase activity and oncogenic potential. We also outline some of the fingerprints of the inhibition mechanisms of PON, IM and DAS, offering a rationale for PON-dependent inhibition of all described BCR-ABL point mutations, including T315I. Since we report that 51% of human tyrosine kinases retain residues equivalent to those forming hydrogen bonds between BCR-ABL and PON, our results may aid the design of inhibitory compounds targeting additional kinases involved in the development of other malignancies.
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MATERIALS AND METHODS
Mutagenesis and Constructs
The BCR-ABL sequence, cloned in the expression vector pcDNA3.1 (Life Technologies, Grand Island, NY, USA), was mutagenized using the QuikChange II XL Site-Direct Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). Incorporation of each mutation was verified by direct sequencing. Every BCR-ABL construct was then amplified by PCR using the indicated forward (FLAG-tag underlined) 5'- 
Purification of BCR-ABL proteins and in vitro kinase assays
BCR-ABL constructs cloned in the pLEX vector were modified to include six histidine codons at the N-terminal to allow protein purification. As a negative control, we generated a kinase inactive (KI) BCR-ABL mutant carrying the K271H substitution (ABL1A numbering) in the ABL kinase domain as previously described (34) . (33)). Unbound forms were generated by manual removal of the inhibitors. Missing residues were rebuilt with MODELLER v9.8. The GROMACS 4.0 program (38) was used to prepare the initial system coordinates, run the MD simulations, and analyze the resulting trajectories. Simulations were performed using the ffamber99sb (39) porting of the AMBER parm99 force field (40) , the TIP3P model for water (41) and the General AMBER Force Field (GAFF) (42) with the AM1-BCC charges (43) for the inhibitors. The systems were minimized and then gradually heated to 300 K with potential restraints on the solute performing several steps of equilibration (44) . After equilibration, the resulting structures were used as a starting point for production of 50 ns MD simulations. Secondary structure analysis 9 was performed with DSSP (45) . The extent of correlated motions was estimated from the correlation matrices on C α positions and represented as correlation webs (46) . The energetic analysis was performed with the Molecular Operating Environment 2012.10 (MOE). The Pose Rescoring method of the Dock module was used to calculate the free energy of binding for each simulated system in complex with the three TKIs.
Representative structures were extracted by cluster analysis (47) Sequence-based predictions of the effect of each mutation were performed with the web servers PROVEAN (49), SIFT (50) and polyphen-2 (51). Images were generated with VMD 1.8.5 (52) and PyMOL 1.2 (Schrodinger Inc).
Multiple sequence alignment of Tyrosine Kinase proteins
Kinase domain sequences were downloaded from the website http://kinase.com. The human tyrosine kinase subset (90 sequences) was extracted and aligned using T-Coffee (53).
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RESULTS
PON binds to the inactive conformation of the BCR-ABL catalytic pocket by generating hydrogen bonds with four amino acids: E286, M318, I360 and D381 (Fig. 1A ) (31). Interestingly, these residues do not undergo substitutions in patients failing TKI therapy (12) (13) (14) (15) . We therefore decided to generate point mutations in these sites and investigate their effect on the expression and kinase activity of both ABL and BCR-ABL. To this end, we engineered eight ABL and eight BCR-ABL constructs displaying two alternative substitutions in E286, M318, I360 and D381. The inserted mutations were deemed conservative if they preserved the physical/chemical properties of the amino acid found in the wild-type sequence, or non-conservative if they altered these characteristics (Table 1) . ABL and BCR-ABL constructs displaying the wild-type sequence or bearing the T315I substitution were used as controls.
E286, M318, I360 and D381 are dispensable for ABL and BCR-ABL protein stability but are critical to preserve BCR-ABL catalytic activity
As point mutations in E286, M318, I360 and D381 have never been reported in CML patients failing a TKI, we hypothesized that substitutions in any of these residues might alter protein stability. To address this issue, we initially employed the above-indicated ABL constructs that were lentivirally transduced in the Ba/F3 cell line.
We found that all ABL mutants were expressed at levels comparable to the wild-type protein and were devoid of catalytic activity ( Fig. 2A ) and transforming potential (Fig. 2B) . Expectedly, the ABL T315I control represented the only exception to these findings as this protein showed high kinase proficiency thereby allowing Ba/F3 proliferation and survival in the absence of IL-3 (54) ( Fig. 2A, B ).
Since wild-type ABL displays very low tyrosine phosphorylation, we could not investigate the influence of each substitution in modulating catalytic activity. We therefore repeated the same experiments employing the corresponding BCR-ABL constructs, exploiting the oncoprotein's constitutive kinase activity (2) . While again all mutants were expressed at levels comparable to those of BCR-ABL WT , any substitution involving residues E286, M318 and D381 completely abrogated their kinase proficiency. The conservative I360T substitution was the only tested variation capable of maintaining BCR-ABL tyrosine phosphorylation (Fig. 2C) . Accordingly, only Ba/F3 cells expressing BCR-ABL I360T survived and proliferated after IL-3 withdrawal, albeit at lower levels than those reported for BCR-ABL WT and BCR-ABL T315I (Fig. 2D ).
To further confirm these results we also performed an in vitro kinase assay using purified BCR-ABL mutants and a previously reported synthetic peptide substrate (55) . The Michaelis-Menten parameters describing 1 1 substrate binding (K m ), maximum rate (V max ) and catalytic constant rate (K cat ) were determined using nonlinear regression fits. A KI BCR-ABL was included in the experiments as a negative control (34) . As expected, seven of eight BCR-ABL mutants generated V max values similar to the KI protein, indicating complete lack of phosphorylation of the synthetic substrate (Fig. 2E, F) . On the contrary, BCR-ABL I360T maintained its kinase activity, although at lower levels than BCR-ABL WT . However, the low K m value displayed by this mutant suggests that minimal substrate concentrations are sufficient to saturate its catalytic activity (Fig. 2F) .
We complemented the experimental validation with an in silico screening of the expected effects of mutations on these positions (Table 2 ). Three sequence-based methods (PROVEAN, SIFT, polyphen-2) consistently predicted the majority of the substitutions as deleterious (labeled 'Not Tolerated' in SIFT or 'damaging' in polyphen-2). A few cases were predicted as deleterious by two of three methods and only selected substitutions in I360 were suggested as possibly tolerated. Sequence-based methods predict the expected effect on both stability and function. To isolate the contribution from protein structure destabilization we performed an analysis of the mutants using MOE. The difference in free energy of folding (⊗⊗G) of the mutants versus the wild-type are also reported in Table 2 . Substitutions on position M318 and I360 are generally destabilizing (⊗⊗G > 1 kcal/mol in bold in Table 2 ), whereas changes on E286 and D381 do not impact stability, suggesting that they are deleterious for their effect on function.
Overall, these results offer a solid rationale for the observed lack of mutations on residues E286, M318 and D381 in CML patients failing TKI treatment. Indeed, both conservative and non-conservative substitutions of these amino acids would result in loss of BCR-ABL catalytic activity, thus compromising its transforming potential. In contrast, a conservative substitution in position 360 appeared to preserve BCR-ABL kinase functionality.
Molecular Dynamics simulations of BCR-ABL mutants I360T and I360R reveal differences in the helix-αC dynamics and in the protein correlated motions
In an effort to better understand the structural and dynamical differences between the KDs of the kinaseproficient I360T and the kinase-deficient I360R, we analyzed the MD trajectories of both BCR-ABL mutants and compared them to the wild-type oncoprotein. In particular, we investigated the correlation between the motions of the different parts of the protein. This was then mapped onto the protein structures using correlation webs, where residues that move together are connected by a line (Fig 3A, B, C top panels). Correlated motions were previously shown to be critical for the activation of the ABL TK domain (26).
We found that the correlated motions of the BCR-ABL I360T KD were mostly located at the bottom of the catalytic pocket. On the contrary the N-terminal of helix-αC is not coupled in its motion to the N-lobe as in the wild-type domain. This provides more freedom of motion to helix-αC that shifts upward and towards the outside (Fig. 3A , B, top panels). We then analyzed the conformational changes and stability of helix-αC by plotting its time evolution along the sequence. We observed that, in BCR-ABL I360T , helix-αC maintained its structure despite retaining the modified orientation for the rest of the simulated time (Fig. 3B , bottom panel, red arrow). BCR-ABL I360R presented a strong decrease in correlated motions compared to both the wild-type oncoprotein and the I360T variant (Fig. 3C, top panel) . The I360R mutant also showed an upward shift of helix-αC that appeared to partially unwind for a 6 ns interval in the middle of the simulation (Fig. 3C , bottom panel, red arrow).
Overall, our results detected differences in the dynamics of BCR-ABL I360T and BCR-ABL I360R that could be related to the diverse catalytic activity of these mutants. However, it remained to be established if different
TKIs would successfully abrogate the catalytic activity of BCR-ABL I360T .
The persistence of some hydrogen bond interactions is critical for successful inhibition of BCR-ABL
I360T kinase activity by TKIs
To investigate whether PON would suppress BCR-ABL I360T kinase activity we simulated this mutant's KD in complex with the drug, and analyzed the average distance of the residues involved in hydrogen bond interactions during the simulations. Since BCR-ABL I360T has never been reported in the literature, we also analyzed this mutant in complex with IM and DAS. Additional simulations were performed with the KDs of BCR-ABL WT and BCR-ABL T315I used as controls. The time evolution of the Root Mean Square Deviation on the C α atoms indicated that all systems rapidly reached equilibrium and remained stable during the simulated time ( Supplemental Fig. S1 ).
PON binds the inactive conformation of the BCR-ABL WT kinase establishing four hydrogen bonds with E286, M318, I360 and D381 (31) (Fig. 4A ). These interactions remained stable during the simulation with the exception of the transient binding with E286 (Fig. 4A) . Since PON does not form hydrogen bonds with Threonine 315, its mutation to Isoleucine should not affect drug binding (56) . Indeed, in our BCR-ABL T315I -PON system, the drug maintained persistent interactions with M318, I360 and D381, while again binding to E286 was transient (Fig. 4B) . Moreover, PON's linear ethynyl linker helped the compound to skirt the steric hindrance phenomenon caused by I315. In the BCR-ABL I360T -PON system, loss of the hydrogen bond with I360 coupled with the weak interaction with E286 did not affect the drug's ability to bind this mutant (Fig. 4C) .
Hence, our simulations suggested that PON should effectively suppress the catalytic activity of the I360T mutant.
Like PON, IM binds the BCR-ABL KD in the inactive conformation generating hydrogen bond interactions with the four residues described above (E286, M318, I360, D381) plus the gatekeeper Threonine in position 315 (32, 57) (Fig. 4D ). Our analysis showed that these interactions persisted during the entire BCR-ABL WT simulation, with small oscillations of the drug's tail that caused one short increase of the distance from I360 in the middle of the simulated time (Fig. 4D) . In the BCR-ABL T315I -IM system, the drug adapted to the mutagenized catalytic pocket thanks to a slightly outward displacement, thus avoiding the increased steric hindrance caused by the Isoleucine side-chain. These changes can be appreciated by comparing the differences in IM structure depicted in Fig. 4D , E. This spatial rearrangement alleviated the clash of bulky residues.
However, in the simulation, the drug lost three of five hydrogen bond interactions compromising optimal protein binding. Indeed, aside from the loss of the hydrogen bond with Threonine 315 because of its substitution with Isoleucine, we observed displacements of the interactions with E286 and I360 (Fig. 4E) . Analysis of BCR-ABL I360T in complex with IM revealed that all hydrogen bond interactions previously shown for the wild-type system were maintained over time, with the exception of the interaction with the mutagenized I360 residue.
Insertion of a Threonine at this site caused a slight change in the conformation of the activation loop resulting in a missing hydrogen bond with the tail of the drug (Fig. 4F) . However, IM binding appeared stable despite this alteration.
Unlike PON, DAS binds the BCR-ABL catalytic pocket in the active conformation forming three hydrogen bond interactions: one with T315 and two with M318 (33) (Fig. 4G) . Hydrogen bonds analysis of BCR-ABL WT in complex with DAS showed that these three points of contact were preserved over the entire simulation (Fig.   4G ). Both biological and clinical evidences have demonstrated that DAS is unable to inhibit the T315I gatekeeper mutation (58, 59) . Simulation of BCR-ABL T315I in complex with DAS showed the expected loss of the critical interaction with I315 (33) (Fig. 4H ). In this case the hydrophobic pocket of the BCR-ABL KD plays a key role in anchoring the phenyl ring of DAS through hydrophobic interactions with several amino acids. Four residues (M290, V299, I313 and F382) all located in this region (33) , showed an increased distance from the inhibitor in the BCR-ABL T315I -DAS system, becoming unavailable for hydrophobic interactions (Supplemental Fig. S2) . Thus, the loss of DAS binding to BCR-ABL T315I can mainly be attributed to changes in the hydrophobic anchoring of the drug. However, DAS did not lose any hydrogen bond interactions with BCR-ABL I360T , implying effectiveness of this drug in inhibiting the kinase activity of the I360T mutant (Fig. 4I ).
In addition to the MD simulations, we also estimated the free energy of binding (⊗G) for each of the TKIs with the simulated systems. The ⊗G values were calculated with MOE and are reported in 6A , B and C, left panels, Fig. 6D ). We next analyzed total tyrosine phosphorylation levels after a 24 hour exposure to the three inhibitors and found that BCR-ABL I360T catalytic activity was efficiently suppressed by each TKI (Fig. 5A , B and C, right panels). Finally, our experiments also confirmed that PON was the only effective compound for the treatment of BCR-ABL T315I (Fig. 5A) , whereas the wild-type oncoprotein was responsive to all TKIs.
Thus, PON, IM and DAS all successfully inhibited BCR-ABL I360T oncogenic activity, as predicted by the hydrogen bond interactions analysis (Fig. 4) . These data also explain why the I360T substitution has never been observed in CML patients unresponsive to TKIs as, in spite of the transforming potential of this mutant, BCR-ABL I360T remains sensitive to multiple kinase inhibitors.
DISCUSSION
Over 100 point mutations involving more than 60 amino acidic residues have been associated with TKI resistance in CML patients (12-15). However, no study has ever reported amino acidic substitutions involving E286, M318, I360 and D381, four residues of the BCR-ABL kinase that generate hydrogen bond interactions with PON (31). In this manuscript we present biological and computational data demonstrating that these four amino acids play a pivotal role in preserving BCR-ABL transforming activity. Indeed, our results suggest thatwith the exception of the I360T substitution -both conservative and non-conservative mutations in E286, M318, I360 and D381 abolish BCR-ABL kinase activity. These findings explain the lack of point mutations in these four amino acidic residues, as any change in these sites would be selected against by either lack of catalytic activity or maintained responsiveness to TKI treatment, as we observed with BCR-ABL I360T . These findings are also corroborated by sequencing data derived from 95 CML patients that either failed IM or achieved suboptimal responses according to the 2009 European Leukemia Net criteria (60) . In these analyses we detected the E286K mutation in one subject, three substitutions at the M318 residue (M318T-V-I) in three patients, and three amino acidic replacements at the I360 residue (I360T-L-S) in five further patients. All substitutions were found in a small percentage of clones (<10%) and none were detected when sequencing the same patients at a later time (Stella S and Vigneri P, unpublished data).
Since the I360T mutation preserved BCR-ABL catalytic activity, we investigated this amino acidic substitution from a computational standpoint, comparing it to the corresponding non-conservative I360R mutation devoid of kinase activity. MD simulations of these two mutants revealed major differences in correlated motions and in the dynamics of helix-αC as compared to wild-type BCR-ABL. I360T displayed strong correlations in the region between the N-and C-lobes of the BCR-ABL catalytic region. We also detected a significant upward shift of helix-αC, which is allowed more freedom and is partially displaced from the core of the domain, with an ensuing tendency in widening the access to the binding cavity. These results suggest a modified arrangement of the ATP pocket that could compromise ATP binding and would be compatible with the reduced kinase activity of this mutant. More dramatic changes were detected in the dynamics of helix-αC in BCR-ABL I360R as in this mutant the helix is looser and has a tendency to unwind. In addition, the domain has lost the inter-lobe communication known to be critical for activation (26). This is in line with the drastic reduction of kinase activity observed for this mutant. In addition, hydrogen bond interaction analyses followed by biochemical and survival assays demonstrated that PON, IM and DAS successfully inhibit BCR-ABL I360T .
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Hydrogen bond analyses also contributed to explain the structural reasons underlying the resistance of the T315I gatekeeper mutation to IM and DAS. The common hypotheses advocated to explain IM and DAS failure in suppressing BCR-ABL T315I is that this substitution mediates drug resistance through a steric hindrance mechanism (61). However, by studying the dynamics of the inhibitor bound systems in-silico, we found that a slightly outward displacement of both IM and DAS allowed these drugs to adapt to the T315I catalytic pocket, thus circumventing the increased steric hindrance caused by the bulky Isoleucine side-chain (Fig. 4D, E) .
Indeed, the steric hindrance generated by the T315I mutation does not lead to complete obstruction of the binding cavity and the flexibility of the drug structure allows for a suitable rearrangement around the bulkier side-chain, unlike cases in which more rigid molecules cannot fit into partially (or totally) occluded pockets. This is generally not visible from a single experimental structure, but requires the simulation of the system to estimate the degree of flexibility of both drug and protein. We therefore investigated other mechanisms contributing to the lack of efficacy of IM and DAS on BCR-ABL T315I . In accordance with previous reports, we found that loss of hydrogen bonds between IM and E286, T315 (replaced by an Isoleucine) and I360 in the BCR-ABL T315I KD played a pivotal role in IM failure against the T315I mutation (30). However, loss of hydrogen bonds was not sufficient to explain BCR-ABL T315I resistance to DAS as only the interaction between T315 and DAS was compromised in the T315I mutant simulations. Upon further investigation we detected a perturbation in the dynamics of amino acidic residues that form hydrophobic interactions with the drug. These alterations are likely to factor heavily in the lack of DAS binding to the T315I mutant.
Further computational investigations of BCR-ABL T315I revealed a net enhancement of correlated motions within the N-and C-lobes as compared to the wild-type oncoprotein (Fig. 6A, B) . The mutation affects the dynamics of the two lobes modifying the access to and the shape of the binding site. The correlations also involve helix-αC (which undergoes a partial unwinding) and the activation loop, suggesting that the T315I mutation dynamically perturbs several structural elements crucially involved in drug binding ( showed intermittent interactions with E286, which is often dislocated from its natural position when helix-αC is destabilized; ii) the drug maintained the same hydrogen bond interactions and the same average distance with all residues involved in hydrophobic contacts in the BCR-ABL WT -PON simulation; iii) there were only minor differences between the BCR-ABL WT -PON and BCR-ABL T315I -PON systems in terms of correlated motions (Fig. 6C, D) , implying that PON seems to "revert" the dynamics of the T315I mutant to those of BCR-ABL wild-type.
The critical issue stemming from our results concerns the implications of the reported findings for future therapeutic developments. CML patients unresponsive to TKI treatment sometimes develop point mutations involving multiple residues within the BCR-ABL KD (12) (13) (14) (15) 62) . It should be emphasized that amino acidic substitutions engaging different residues of a catalytic domain are not a prerogative of the ABL kinase, as identical phenomena (including mutations of the gatekeeper Threonine) have been reported in patients diagnosed with lung cancer or gastro-intestinal tumors failing Epidermal Growth Factor Receptor or c-KIT inhibitors, respectively (63, 64) . Two different approaches have been pursued to address these problems.
Several companies have synthesized irreversible TKIs that, unlike reversible inhibitors (e.g. IM), generate covalent bonds with specific amino acidic residues (usually Cysteines but also Serines, Threonines or Lysines)
of their substrate(s). While highly effective, irreversible TKIs have often been associated with increased (sometimes limiting) toxicities that have hindered their clinical development (65) . An alternative approach has been to design compounds that do not interact with the critical gatekeeper residue of the substrate kinase (66).
The caveat of this method is that -theoretically -amino acidic substitutions in residues other than the gatekeeper could induce resistance to these drugs. However, to date, no single point mutations have been associated with resistance to PON. Our data suggest that the lack of mutations causing PON failure derives from the fact that this inhibitor forms hydrogen bonds with four critical residues (E286, M318, I360 and D381) of the BCR-ABL KD that, if mutated, would compromise the transforming ability of the oncoprotein. Hence, changes in any of the above-mentioned four residues would be selected against by a lack of kinase activity or by maintained responsiveness to TKIs (BCR-ABL I360T ). Interestingly, when we analyzed the twelve known PON biological targets (9, 67), we found that these tyrosine kinases conserved the ABL E, I/V and D residues but displayed different substitutions in place of M318 (Fig. 7A) . These results suggest a structural scenario in which E286, M318, I360 and D381 are "untouchable" residues for the ABL kinase, but only E, I and D are critical for the remaining PON targets as the Methionine in position 318 can be replaced by either an Alanine or a Cysteine.
Remarkably, residues equivalent to ABL E286, M318, I360 and D381 are conserved in 46 of 90 (51%) human tyrosine kinases including both receptor and non-receptor proteins (Fig. 7B) . Forty-two of these 46 tyrosine kinases were tested for PON responsiveness in a previously published in vitro kinase assay and 25 of 42 (59%) were efficiently inhibited by the drug (IC 50 <20 nM) (9). While we can't offer a detailed explanation as to why PON lacks efficacy on the remaining 17 kinases, several observations should be kept in mind. Specifically: i) 1 8 while a sequence alignment suggests that E, M, I and D residues are preserved in these TKs, a large-scale Molecular Dynamics study would be necessary to confirm that these amino acids conserve a similar role in protein flexibility compared to the ABL KD, in line with recent evidence that selective inhibition of TKs could also be connected to differences in their intrinsic dynamics (19, 22) ; ii) since our current structural information is mostly limited to the catalytic domain of multiple tyrosine kinases, we can not account for the significant modifications that other portions of the protein may exert on the catalytic pocket, heavily affecting PON binding; iii) likewise, the shape and orientation of the drug binding pocket of each TK may present subtle differences that could partially or completely abrogate its interaction with PON. Hence, preservation of E, M, I
and D residues in positions equivalent to those of the ABL KD appears to be necessary but not sufficient to predict PON binding to other TKs.
In summary, we report here the identification of four amino acidic residues (E286, M318, I360 and D381) that are critical for BCR-ABL catalytic activity and leukemogenic potential. We also find that these amino acids are conserved in several human tyrosine kinases and are likely to represent unmodifiable residues that contribute to the proper structural folding and enzymatic activity of these proteins. Small molecule inhibitors targeting these amino acids in other tyrosine kinases might be of great clinical interest to avoid the emergence of resistance due to point mutations. Nicolini, F. E., Ibrahim, A. R., Soverini, S., Martinelli, G., Muller, M. C., Hochhaus, A., Dufva, I. H., Kim, D. W., Cortes, J., Mauro, M. J., Chuah, C., Labussiere, H., Morisset, S., Roche-Lestienne, C., Lippert, E., Hayette, S., Peter, S., Zhou, W., Maguer-Satta, V., Michallet, M., Goldman, J., Apperley, J. human tyrosine kinases displaying residues equivalent to E286, M318, I360 and D381 identified in the BCR- 
